65,437 trials
Systemic Lupus Erythematosus · Active Cutaneous Lupus Erythematosus
Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037
Graft vs Host Disease
Primary: Matched Related Transplants Who Develop Grade II-IV Acute Graft Versus Host Disease (GVHD). — 3 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Splenic Response Rate at Week 24 — 57; 64; 158; 153 Participants — p=0.014
Tree Nut Allergy
Primary: Effectiveness of Walnut OIT on Clinical Desensitization to Test Tree Nut as Measured by Change in Cumulative Tolerated Dose From Baseline to Week 38 at Oral Food…
Fibromyalgia · Multiple Sclerosis · Osteoarthritis
Primary: Changes From Baseline in Physical Activity — 0.36; 0.31; 0.43; 0.76 units on a scale
HIV-1 Infection
Primary: Number of Participants w/ at Least One ≥ Grade 3 Adverse Event That is Possibly or Definitely Related to Vorinostat (VOR) or HIV-specific T Cell (HXTC) — 0 Participants
Chronic Pain · Chronic Lower Back Pain · Back Pain
Primary: Changes in Patient Reported Pain and Discomfort — 47; 13; -30; -18 percent change from baseline
Fetal Growth Retardation
Primary: Number of Participants for Which Intervillous Placental Blood is Detected — 3 Participants
Acne Vulgaris
Primary: Number of Subjects With Adverse Events Ongoing From Parent Study at Start of Study NI-AC303) — 59; 62 Participants
Depression · Anxiety · Post Traumatic Stress Disorder
Primary: 9-item Patient Health Questionnaire (PHQ-9) — -3.23 units on a scale
Gestational Diabetes Mellitus
Primary: Weight Loss — 0; 0; 2 Participants
Wound Heal
Primary: Time to Complete Wound Re-epithelialization on the Head — 41.6; 43 days
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Postpartum Pregnancy-Induced Hypertension · Postpartum Preeclampsia · Hypertension, Pregnancy-Induced
Primary: Mean Arterial Blood Pressure (MAP) — 88.9; 86.8 mmHg
Healthy
Primary: Pharmacokinetic Outcome Measures [AUC0-inf] for Part 2 — 910.9; 897.7; 926.3 day*μg/mL